Patient Case Mrs X Provided compliments of Mary Gunther, BScPharm, ACPR
|
|
- Edmund Welch
- 6 years ago
- Views:
Transcription
1 Patient Case Mrs X Provided compliments of Mary Gunther, BScPharm, ACPR ID: Mrs X is a female in her mid sixties admitted for a CHF exacerbation CC: 1. 2 week history of increasing weakness, weight gain, pedal edema, and SOBOE 2. Bilat pleuritic chest pain, worse on inspiration GP thought MSK cause, gave T3 s and cyclobenzaprine confusion, hallucinations 3. Severe achy foot pain x 3d (originating from swollen big toe on left foot) PMHx and Current Medications: CHF (LVEF = 45 50% in 2007) AFib HTN Furosemide 80 mg BID Metolazone 2.5 mg MWF ASA 81 mg daily Clopidogrel 75 mg daily Amiodarone 200 mg daily Bisoprolol 2.5 mg daily Amlodipine 10 mg daily Lisinopril 40 mg daily Dyslipidemia T2DM Hypothyroidism Depression Gout Chest Pain Rosuvastatin 10 mg daily Nil (diet controlled) Levothyroxine 0.1 mg daily Citalopram 40 mg daily Nil last flair was 3 years ago Cyclobenzaprine and T3 s PRN Review of Systems (done at admission) Vitals: BP = 115/45 HR = 90 (irreg) RR = 22 O2 = 92% on 4L (on 2 4L home O2 for 2.5 years) General: +++ obese, alert and oriented x3, NAD CV: S1/S2 irreg ireg, no S3/S4, + pedal edema Resp: decreased AE bilat, crackles R>L Labs: Na= 143 K= 3.5 SCr = 141 (BL ~ 120) Hgb = 119 Plt = 237 WBC = 11.7 A1C = 7.0% TSH = 3.11 Trop < 0.10 Lipids: TC = 3.7, TG = 1.52, HDL = 1.09, LDL = 1.91, TC/HDL = 3.4 Diagnostic Imaging CXR: cardiomegaly, vascular redistribution, c/w CHF CT head: no acute infarct, no hemorrhage ECG: AFib
2 Pharmacy Care Plan Worksheet Example (provided compliments of Mary Gunther, BScPharm, ACPR) MEDICAL CONDITIONS and/or DRPs List and prioritize each medical condition first, followed by any DRPs for a given condition. Although some medical conditions may not have a DRP, a care plan is still necessary for ongoing patient monitoring. DRP Categories: unnecessary drug additional drug required ineffective drug dose too low adverse drug reaction/interaction dose too high nonadherence AFib Mrs X is at risk of cardioembolic stroke (CHADS2=3) secondary to suboptimal antithrombotic GOALS OF THERAPY ALTERNATIVES RECOMMENDATIONS/ PLAN For each medical condition and/or DRP state desired goals of /timeframe. Goals: cure, prevent, slow/stop progression, reduce/eliminate symptoms, normalize a lab value. Consider realistic goals determined through patient discussion. Goals of are measurable or observable parameters that are used to evaluate the efficacy and safety of. To provide adequate stroke prophylaxis while not placing patient at an unreasonable risk of harm, on an ongoing basis Pt worried about bleeding (ICH in 2003) Compare relevant drug and non drug therapies that will produce desired goals. List the pros and cons of each. Indication Efficacy Adherence Safety Cost/coverage Alternatives to be weighed on relative risk of bleeding vs stroke on each regimen Continue ASA and clopidogrel PRO: no lab monitoring required; CON: same bleeding risk as warfarin, efficacy less than warfarin, cost, ASA alone PRO: lowest bleeding risk of all options; CON: Least effective option Warfarin PRO: effective for reducing stroke, also has bleeding risk similar to clopidogrel + ASA; CON: INR monitoring required (NOTE: dabigatran was not available for AFib at time of this case) In collaboration with the patient and other health care providers, select the best alternative and implement the plan. Provide a rationale for the chosen plan. Drugs: correct drug, formulation, route, dose, frequency, schedule, duration, medication management. Non drug: non drug measures, education, patient referral. Patient very worried about developing another ICH and would like to avoid warfarin. PLAN: Continue ASA and clopidogrel as per pt wishes (as discussed with internist Dr M) MONITORING PARAMETERS Determine the parameters for monitoring efficacy and safety for each. Clinical & laboratory parameters The degree of change The time frame?absence of stroke?absence of ICH Other bleeding (decreased Hgb, blood in stool/urine) FOLLOW UP Determine who, how and when follow up will occur. Dr M will follow up in HF clinic and assess if dabigatran will be option in the future Copyright 2011, Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta 1
3 CHF Gout Mrs X is experiencing an acute CHF exacerbation additional Mrs X is experiencing a gout flare up additional drug Confusion/Delirium (recent onset) Mrs X is experiencing an adverse drug reaction (T3# and cyclobenzaprine reassessment Improve pt s presenting symptoms (weakness, weight gain, pedal edema, and SOBOE) back to her baseline within 1 week To reduce foot pain to an acceptable level within 24 hours To treat pt s chest pain (thought to be MSK) to the point that she is comfortable without causing adverse effects Diuresis alone (furosemide) will likely alone not be enough Cardioversion out of AFib (thought to be a significant contributor to acute decompensation) cardioversion increase in amiodarone NSAID (not viable alternative as should be avoided in CHF/AKI) Colchicine (how to dose? 0.6 mg Q2 3H until resolution vs fixed low dose eg. 0.6 mg Q12H) Prednisone (use as last option) Reduce doses of Tylenol 3 and cyclobenzaprine Acetaminophen alone NSAID Furosemide 80 mg IV BID until euvolemic Tried DC cardioversion unsuccessful Started on amiodarone infusion 60 mg/h x 6h, then 30 mg/h x 18h, then resume amiodarone 200mg daily NOTE: beta blocker dose not at target, but do not want to increase dose during acute CHF exaccerbation Colchicine 0.6 mg Q12H (pain only 5/10, will try lower dose first) NSAID not appropriate due to AKI and CHF/edema Pain not bothering pt at present d/c Tylenol 3 and cyclobenzaprine, will restart acetaminophent alone if pain recurs avoid NSAID given CHF and kidney function Daily improvement in SOB/edema Daily weights until return to dry weight (=130 kg, currently 135 kg) K+ level: keep above 3.5 mmol/l (currently 3.5) HR <80 bpm (ie. control of AFib) within 24h of amiodarone infusion Resolution of pain Watch for diarrhea and neutropenia Educate pt about diarrhea (may be tied to efficacy) Follow for recurrence of pain Ensure confusion/delirium resolves When euvolemic, pharmacist will ensure home doses of metolazone and furosemide PO resumed (Dr M will reassess home diuretics in clinic) When acute exacerbation resolves, will reassess to see if HR/BP can tolerate increased bisoprolol dose Resolved quickly; agent D/C d prior to discharge. As pt has infrequent flare ups, no chronic treatmentl needed Pt will see GP if pain recurs. Pt aware Tylenol 3 s and cyclobenzaprine likely to blame for confusion, and advised to avoid in future. Also reinforced avoiding NSAIDs. Copyright 2011, Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta 2
4 Acute on Chronic Renal Failure (or AKI) To avoid any additional injury to the kidneys while the acute renal failure is resolving Hold furosemide Hold ACEI Hold ACEI until SCr back to baseline Continue furosemide (good cardiac output will likely help AKI resolve) Daily SCr until returned to baseline (~120 mcmol/l) Pharmacist will follow SCr and restart ACEI when appropriate HTN No issues To maintain BP <130/80 on an ongoing basis both in hospital and at home Continue current amlodipine, bisoprolol (Lisinopril temporarily on hold) BP < 130/80 (currently achieved) Patient monitors BP at home and is aware of targets No S/Sx of hypotension (dizziness, fainting) Continue to monitor BPs while in hospital Pt will follow up with Dr M for chronic management after discharge Dyslipidemia No issues To maintain lipid parameters in accordance with Canadian guidelines for high risk patients (LDL <2) on an ongoing basis Current LDL is at target No alternatives required Continue current rosuvastatin Lipid panel 1 2x/year No new muscle soreness/weakness No ALT, but no clinical s/s of liver problems No active f/u by pharmacist; low priority issue T2DM No issues To maintain A1C < 7.0% on an ongoing basis A1C checked and within desired range diet A1C 1 2x/year To be followed as outpatient (Dr M) upon discharge) Hypothyroidism No issues Depression No issues To maintain TSH within normal range (0.04 4) on an ongoing basis (hyperthyroid can worsen AF) To achieve and maintain a good enough mood to be able to function and have QOL acceptable to the patient TSH checked and within normal range levothyroxine Pt reports no problems with mood/affect treatment with citalopram TSH 1 2x/year Maintenance of pt s current mood/mental state Form adapted with permission from the Division of Pharmacy Practice, Leslie Dan Faculty of Pharmacy, University of Toronto, Will follow up with GP as per usual Will follow up with GP as per usual Copyright 2011, Faculty of Pharmacy & Pharmaceutical Sciences, University of Alberta 3
5 DOCUMENTATION FROM PATIENT CHART FOR MS. X Provided as example, compliments of Mary Gunther, BScPharm, ACPR Pharmacist Note ASA and Plavix September 14, :45h Asked by team to review evidence for combination use of ASA and clopidogrel in atrial fibrillation as compared to warfarin for benefit (stroke reduction) and risk (major bleeding). Data: Identified 2 recent major trials: ACTIVE A and ACTIVE W. ACTIVE A ASA + clopidogrel vs ASA alone. Found that combination of ASA+clopidogrel is associated with a decrease in vascular event risk that is equal to the increase in risk of major bleeding ACTIVE W ASA + clopidogrel vs warfarin. Found warfarin is superior to combination of ASA+clopidogrel in preventing vascular events, and has the same risk of major bleed. As per pt, her internist who follows her at the heart function clinic (Dr. M) suggested she take ASA + clopidogrel instead of warfarin for her high risk atrial fibrillation (CHADS=3) to reduce risk of ICH (pt had ICH while on warfarin in 2003 requiring ICU admission). Assessment/Plan: ASA + clopidogrel may carry the same major bleeding risk as warfarin, but without as significant of a benefit in the reduction of stroke. Will discuss with patient. M. Gunther, BSc Pharm ****** Pharmacist Note September 15, h Data: Met with patient to discuss relative risks of ASA alone vs ASA + clopidogrel vs warfarinsee previous note for additional details. Assessment/Plan: Pt very afraid of developing another ICH; discussed with patient that literature suggests ASA and clopidogrel does not appear to have a lower major bleeding rate than warfarin, so if she s unwilling to accept the bleeding risks of warfarin, perhaps she should consider ASA alone. Pt stated that she wanted us to consult with her internist at heart function clinic, Dr M, prior to making any decisions. Will contact Dr M and ask him to review. M. Gunther, BSc Pharm ****** Physician Note September 17, h Asked by team and pt to review antithrombotic for atrial fibrillation. Met with patient and have discussed results of ACTIVE A and ACTIVE W. Reluctant to put pt back on warfarin given prior ICH, but given CHADS=3, do not think ASA alone will be adequate. Pt is tolerating ASA + Plavix well will continue current treatment for now. Pt may be good candidate for dabigatran in future (equal to warfarin in stroke reduction, but lower risk of ICH). Will follow and reassess when pt sees me in clinic after discharge. Dr. M
Reason for referral: provide patient education on management of hypoglycemia and glucose monitor
Meet Robin Sawyer (otherwise known as PT 1): Let s Create a Care Plan! Reason for referral: provide patient education on management of hypoglycemia and glucose monitor History of present illness: 40 45
More informationTopic: Chronic Heart Failure Cases for Monday s March 21th lecture.
1 Phar6122: CV section Date: 3/10/05 Topic: Chronic Heart Failure Cases for Monday s March 21th lecture. Directions: This handout includes three chronic heart failure cases of increasing difficulty. In
More informationGeriatric Grand Rounds
Geriatric Grand Rounds Tuesday, April 13, 21 12: noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital In keeping with Glenrose Rehabilitation Hospital policy, speakers participating in this
More information5AB Dysrhythmia Interpretation and Management 2016
5AB Dysrhythmia Interpretation and Management 2016 How to complete your biennial ECG review: A website has been created that contains the basic review information. Use this as a reference during your review.
More informationThe Atrial Fibrillation Clinic in Llanelli. Dr Lena Marie Izzat Consultant Cardiovascular Physician
The Atrial Fibrillation Clinic in Llanelli Dr Lena Marie Izzat Consultant Cardiovascular Physician Llanelli Multidisciplinary AF Clinic Went live January 2009 Based on the fact that Carmarthenshire has
More informationTopic: Chronic Heart Failure Cases for Monday s March 21th lecture.
1 Phar6122: CV section Date: 3/21/05 Topic: Chronic Heart Failure Cases for Monday s March 21th lecture. Directions: This handout includes three chronic heart failure cases of increasing difficulty. In
More informationAF in the ER: Common Scenarios CASE 1. Fast facts. Diagnosis. Management
AF in the ER: Common Scenarios Atrial fibrillation is a common problem with a wide spectrum of presentations. Below are five common emergency room scenarios and the management strategies for each. Evan
More informationCase Summary. Workshop Overview. Mr. M
9:00 10:30 Workshop Overview Mr. M Who is this document primarily intended to reach? What is the format? How soon should I see a newly referred heart failure patient? How often should my heart failure
More informationATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION
ATRIAL FIBRILLATION: REVISITING CONTROVERSIES IN AN ERA OF INNOVATION Frederick Schaller, DO, MACOI,FACP Adjunct Clinical Professor Touro University Nevada DISCLOSURES I have no financial relationships
More informationDifficult to Treat Hypertension
Difficult to Treat Hypertension According to Goldilocks JNC 8 Blood Pressure Goals (2014) BP Goal 60 years old and greater*- systolic < 150 and diastolic < 90. (Grade A)** BP Goal 18-59 years old* diastolic
More informationNEWLY DETECTED ATRIAL FIBRILLATION. Edgar S. Carell, M.D. Director, Vascular Medicine Clinic West Suburban Cardiology
NEWLY DETECTED ATRIAL FIBRILLATION Edgar S. Carell, M.D. Director, Vascular Medicine Clinic West Suburban Cardiology 68 y/o woman complains of - generalized fatigue - mild DOE - never eats but keeps gaining
More informationA patient with acute heart failure and renal impairment ACCA Masterclass 2017
A patient with acute heart failure and renal impairment Dr Sofie Gevaert Mister P. J.M., 67-years-old Cardiac risk factors: Ex-smoker, AHT, Type 2 diabetes, BMI 43, Hyperlipidaemia Medical history: 2009:
More informationCardiovascular Pharmacotherapy Update
Cardiovascular Pharmacotherapy Update Debby Caraballo, PharmD, PhC, BCPS April 30 th 2011 Objectives Review recent updates in cardiovascular pharmacotherapy Discuss the updates to Afib, UA/NSTEMI, STEMI/PCI
More informationHeart Failure: Current Management Strategies
Heart Failure: Current Management Strategies CSHP Fall Education Session- September 30th, 2017 Carolyn MacKinnon & Tamara Matchett BscPharm, ACPR Candidates Objectives 1. Describe the pathophysiology &
More informationCost and Prevalence of A fib. Atrial Fibrillation: Guideline Directed Treatment. Prevalence of A Fib. Risk Factors for A Fib. Risk Factors for A Fib
Atrial Fibrillation: Guideline Directed Treatment Melissa Wendell, FNP-C, MSN Heart Failure - Lead Nurse Practitioner, Aspirus Wausau Hospital and Aspirus Cardiology Cost and Prevalence of A fib 33.5 million
More informationHOW TO USE THE CLINICAL PATHWAY
CONGESTIVE HEART FAILURE CLINICAL PATHWAY ACUTE STAGE HANOVER AND DISTRICT HOSPITAL 1. 2. 3. 4. INCLUSION CRITERIA Primary admitting diagnosis is Congestive Heart Failure as defined by New York Heart Association.
More information:{ic0fp'16. Geriatric Medicine: Optimal Heart Health Amid Changing Guidelines. (and the Evidence for When to Stray) Kevin Overbeck, DO
:{ic0fp'16 ACOFP 53 rd Annual Convention & Scientific Seminars Geriatric Medicine: Optimal Heart Health Amid Changing Guidelines (and the Evidence for When to Stray) Kevin Overbeck, DO Optimal Heart Health
More informationHOW TO USE THE CLINICAL PATHWAY
1. 2. 3. 4. INCLUSION CRITERIA Primary admitting diagnosis is Congestive Heart Failure as defined by New York Heart Association. EXCLUSION CRITERIA Patients less than 19 years of age. HOW TO USE THE This
More informationSacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP
Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure Elizabeth Pogge, PharmD, MPH, BCPS, FASCP Disclosure Elizabeth Pogge reports no actual or potential conflicts of interest
More information8:30-10:30 WS #4: Cardiology :00-13:00 WS #11: Cardiology 101 (Repeated)
Professor Ralph Stewart Cardiologist Auckland City Hospital Green Lane Cardiovascular Research Unit Auckland Heart Group Fiona Stewart Cardiologist Green Lane Hospital National Women's Hospital Professor
More informationDiabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
More informationHOW TO USE THE CLINICAL PATHWAY
ACUTE CORONARY SYNDROMES CLINICAL PATHWAY ACUTE STAGE GREY BRUCE HEALTH SERVICES Lion's Head Markdale Meaford Owen Sound Southampton Tobermory Wiarton PATIENT ID INCLUSION CRITERIA Patients who present
More informationNephrotic Syndrome. Sara Alsharhan PharmD candidate, KSU 2014
Nephrotic Syndrome Sara Alsharhan PharmD candidate, KSU 2014 Outline Introduction Nephrotic syndrome classifications Signs and symptoms Diagnoses Management Complications Monitoring Case presentation Introduction
More informationAcute Stroke with Alteplase Administration Order Set
Review Due Date: 2017 October PATIENT CARE DERS Weight: Adverse Reactions or Intolerances Drug No Yes (list) Food No Yes (list) _ Latex No Yes Admission Admit to Neurology service: Dr. Critical Care Diagnosis:
More informationOut with the old, in with The 2010 Atrial Fibrillation Guidelines
Out with the old, in with The 2010 Atrial Fibrillation Guidelines Kseniya Chernushkin B.Sc.(Pharm.), VCH/PHC Pharmacy Resident Mary Elliot B.Sc.(Pharm.), VCH/PHC Pharmacy Resident March 22, 2011 Outline
More informationHOW TO USE THE CLINICAL PATHWAY
CONGESTIVE HEART FAILURE CLINICAL PATHWAY ACUTE STAGE GREY BRUCE HEALTH SERVICES Lion's Head Markdale Meaford Owen Sound Southampton Tobermory Wiarton 1. 2. 3. 4. INCLUSION CRITERIA EXCLUSION CRITERIA
More informationEdoxaban. Direct Xa inhibitor Direct thrombin inhibitor Direct Xa inhibitor Direct Xa inhibitor
This table provides a summary of the pharmacotherapeutic properties, side effects, drug interactions and other important information on the four anticoagulant medications currently in use or under review
More informationNew Concepts in Acute Coronary Syndromes Beyond 2000 (XX) Interactive Case Presentations
New Concepts in Acute Coronary Syndromes Beyond 2000 (XX) Interactive Case Presentations Dr. Richard Bon Surrey Memorial Hospital, Surrey, BC Canadian Cardiovascular Congress 2014 October 26, 2014 Conflicts
More informationAdmit date (YYYY/MM/DD): Cardiologist On-Call: Diagnosis: Lab Tests. CBC, Electrolytes, Urea, Creatinine, Glucose, INR, PTT, Urinalysis
of nurse 1. Admit under ward Attending Physician: Dr. Admit date (YYYY/MM/DD): Cardiologist On-Call: Diagnosis: Lab Tests 2. On admission (if not already performed in Emergency Department or in Coronary
More informationAtrial Fibrillation and the NOAC s. John Raymond MS, PA-C, MHP February 10, 2018
Atrial Fibrillation and the NOAC s John Raymond MS, PA-C, MHP February 10, 2018 Pathogenesis EPIDEMIOLOGY Arrhythmia-related hospitalisations in the US Ventricular fibrillation 2% Atrial fibrillation 34%
More informationChallenges in Anticoagulation Bridging and Emerging Therapies. Disclosures and Relationships. Objectives. Dr. Cumbler has no conflicts of interest
Challenges in Anticoagulation Bridging and Emerging Therapies Ethan Cumbler MD FACP Associate Professor of Medicine Hospitalist Medicine Section University of Colorado Denver 2011 Disclosures and Relationships
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More information2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much?
2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much? Dr. Shelley Zieroth University of Manitoba @ShelleyZieroth @CanHFSociety Disclosures Consulting/Advisory Board: Amgen, Astra
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationBEFORE the session. Sodium & Water Assessment & Therapeutics. LMPS Residents
BEFORE the session 1. Get Loewen s Sodium & Water Assessment & Therapeutics 1-pager at www.peterloewen.com/made 2. Read McGee S, Abernethy WB, Simel DL. Is this patient hypovolemic? JAMA 1999;281:1022-9
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationMedical Apps for Cardiology Uses. There s an App for That!
Medical Apps for Cardiology Uses There s an App for That! Audience Participation Question #1 1. ASCVD Risk App What is the predicted 10 year CV event rate for a 57 y/o black male patient with treated
More informationCases & Panel Discussion
TSOACs What s the difference anyway? Controversies in selection and complications Augustus Hough, PharmD, BCPS (AQ-Cardiology) Clinical Pharmacy Specialist West Palm Beach VA Medical Center Larry Lopez
More informationComplicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital
Complicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital Complicated issues in GI bleeding; Survey results from internists Optimal resuscitation
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationControversies in Atrial Fibrillation and HF
Controversies in Atrial Fibrillation and HF Dr.Yahya Al Hebaishi Cardiac electrophysiology division, PSCC, Riyadh Atrial Fibrillation: Rate or Rhythm? HF and AF: the twin epidemic of cardiovascular disease.
More informationUse of Anticoagulants in Geriatrics: Current Evidence and Special Considerations
Use of Anticoagulants in Geriatrics: Current Evidence and Special Considerations Aryn You, PharmD Assistant Professor, Pharmacy Practice The Daniel K. Inouye College of Pharmacy Aida Wen, MD Associate
More informationCase Discussion. 18 th Annual UCSD Heart Failure Symposium
Case Discussion 18 th Annual UCSD Heart Failure Symposium In your office today is a returning patient and an eager-to-please 3 rd year medical student. You review HF s history as the student is in the
More informationCardiology. Self Learning Package. Module 5: Pharmacology: Treatment of Acute Coronary. Prevention
Cardiology Self Learning Package Module 5: Pharmacology: Treatment of Acute Coronary Syndromes, Module 5: Pharmacology: Hyperlipidaemia, Treatment of Acute Coronary Hypertension, Symdrome, Hyperlipidaemia,
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationThe Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now. Bradley A. Hardin, MD Richard F.
The Role of Oral Anticoagulants in Atrial Fibrillation: What You Need to Know Now Bradley A. Hardin, MD Richard F. Otten, MD, FACC Outline Atrial Fibrillation Overview Overview of New Oral Anticoagulants
More informationPhysician Orders ADULT: PCI Post Procedure Plan
Initiate Orders Phase Care Sets/Protocols/PowerPlans Initiate Powerplan Phase Phase: PCI Post Procedure Phase, When to Initiate: Initiate Powerplan Phase Phase: Post Cath/PCI Hydration Protocol Phase,
More informationA patient with decompensated HF
A patient with decompensated HF Professor Michel KOMAJDA University Pierre & Marie Curie Pitie Salpetriere Hospital Department of Cardiology Paris (France) Declaration Of Interest 2010 Speaker : Servier,
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationAtrial Fibrillation Topics for Today. Clinical Controversies Management of Atrial Fibrillation. Atrial Fibrillation in the ER Topics for Today
Clinical Controversies Management of Atrial Fibrillation Yerem Yeghiazarians, M.D. Associate Professor of Medicine Leone-Perkins Family Endowed Chair in Cardiology Atrial Fibrillation Topics for Today
More informationDual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015
Dual antiplatelet therapy (DAPT) in the era of Novel Oral Anticoagulants (NOACs) SACIS 2015 Wesam A Alhejily MD FRCPC FACP FACC FSCAI Assistant Professor of Medicine Chief Of Adult Cardiology Consultant
More informationTarget dose achievement of evidencebased medications in patients with heart failure with reduced ejection fraction attending a heart failure clinic
Target dose achievement of evidencebased medications in patients with heart failure with reduced ejection fraction attending a heart failure clinic June Chen 1, Charlotte Galenza 1, Justin Ezekowitz 2,3,
More informationALLHAT. U.S. Department of Health and Human Services. National Institutes of Health. National Heart, Lung, and Blood Institute
U.S. Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute Review of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More informationCARDIAC REHABILITATION PROGRAMME:- MEDICATION
CARDIAC REHABILITATION PROGRAMME:- MEDICATION AIM OF THIS SESSION Understand the reasons for taking your medications, Discuss the common side effects associated with these medications - knowing when to
More informationDemystifying the Complex Patient
Demystifying the Complex Patient Jay Reaume, BSc, BScPhm, RPh, CDE Suzanne Singh, BScPhm, ACPR, PharmD, RPh May 30, 2015 Disclosures Jay Reaume No conflicts of interest to disclose Suzanne Singh No conflicts
More informationSAMPLE SAQ QUESTIONS RCPSC General Internal Medicine Examination (2015)
SAMPLE SAQ QUESTIONS RCPSC General Internal Medicine Examination (2015) Question 1 You are called by a relatively inexperienced physician practicing in a rural emergency department 3 hours from your center.
More informationAtrial Fibrillation is Common. The (S)Low-down on Rapid Afib Resuscitation Step ED Dx - Rx 4/4/2017. There Are 5 Causes of Atrial Fibrillation
The (S)Low-down on Rapid Afib Resuscitation 2017 Corey M. Slovis, M.D. Vanderbilt University Medical Center Metro Nashville Fire Department Nashville International Airport Nashville, TN Atrial Fibrillation
More informationProgram Metrics. New Unique ID. Old Unique ID. Metric Set Metric Name Description. Old Metric Name
Program Metrics The list below includes the metrics that will be calculated by the PINNACLE Registry for the outpatient office setting. These include metrics for, Atrial Fibrillation, Hypertension and.
More informationPatient Encounters in the Primary Care Setting
Patient Encounters in the Primary Care Setting Carmine D Amico, D.O. Clinical Cases Overview Learning objectives Clinical case presentations Questions for audience participation 1 Clinical Cases Learning
More informationNewer Anti-Anginal Agents and Anticoagulants
Newer Anti-Anginal Agents and Anticoagulants Satish Gadi, MD FACC FSCAI Interventional Cardiologist, Cardiovascular Institute of the South (CIS) Baton Rouge Clinical Assistant Professor, Tulane University
More informationCryptogenic Stroke: A logical approach to a common clinical problem
Cryptogenic Stroke: A logical approach to a common clinical problem Alphonse M. Ambrosia, DO, FACC Interventional Cardiologist CardioVascular Associates of Mesa Mesa, Arizona Speakers Bureau Boston Scientific
More informationWho Needs Admission and Who can go home?
Who Needs Admission and Who can go home? Where is the presentation (clinic or ER)? Time of onset/duration Can symptoms be relieved? Stroke risk reduction Can adequate heart rate control be achieved? Is
More informationInterQual Acute Criteria: Demonstration of Condition Specific Subsets
InterQual Acute Criteria: Demonstration of Condition Specific Subsets February 24, 2011 Today s Presenters Lollie Dubiel, RN, BSN Sr. Product Manager McKesson Laura McIntire, RN, BSN, MA Clinical Lead
More informationAtrial Fibrillation. Epidemiology. Goals 11/12/2012. Faithful marker for age and underlying cardiopulmonary disease
Atrial Fibrillation Goals the emerging epidemic Rate Control Thromboembolism and anticoagulation Cardioversion: When, How, and Why 1st time AF < 48hr 1st time AF > 48hr PAF < 48 hr. PAF > 48 hr. Eric R.
More informationAlan Barber. Professor of Clinical Neurology University of Auckland
Alan Barber Professor of Clinical Neurology University of Auckland Presented with L numbness & slurred speech 2 episodes; 10 mins & 2 hrs Hypertension Type II DM Examination pulse 80/min reg, BP 160/95
More informationTransitions of Care & Medication Reconciliation Ashley King, PharmD, BCGP Clinical Pharmacist LECOM Health March 2018
Transitions of Care & Medication Reconciliation Ashley King, PharmD, BCGP Clinical Pharmacist LECOM Health March 2018 Objectives Identify when to complete medication reconciliation Understand the importance
More informationJock Murray Constance LeBlanc Jennie Leverman Caitlin Wolfe
Jock Murray Constance LeBlanc Jennie Leverman Caitlin Wolfe Disclosures ARTICLE #1 Background Physicians are reluctant to use IV contrast for CT scans in patients with impaired renal function We feel that
More informationThe CCS Heart Failure Companion: Bridging Guidelines to your Practice
The CCS Heart Failure Companion: Bridging Guidelines to your Practice Looking for practical answers concerning optimal heart failure care? The CCS Heart Failure Guidelines Companion can help. The Canadian
More informationMRCP(UK) PACES. INFORMATION FOR THE CANDIDATE Training Scenario N 001 SAMPLE HOST CENTRE Station 5: BRIEF CLINICAL CONSULTATION
INFORMATION FOR THE CANDIDATE MRCP(UK) PACES Station 5: BRIEF CLINICAL CONSULTATION Patient details: Mrs XX aged 45. Your role: You are the doctor in the medical admissions unit. You have 10 minutes with
More informationwas admitted to the Cardiology Service at the from Y /M /D to Y / M / D under the care of Dr..
Patient: was admitted to the Cardiology Service at the from Y /M /D to Y / M / D under the care of Dr.. Discharge Diagnoses include: q CAD-CCS Class: m 0 m 1 m 2 m 3 m 4 q Unstable angina q Non STEMI (non-st
More informationBest Practices in Acute Care Precepting at the Sharp Chula Vista Medical Center Medicine Rotation
Best Practices in Acute Care Precepting at the Sharp Chula Vista Medical Center Medicine Rotation Pratima Patel, PharmD Clinical Pharmacist Medicine Rotation Preceptor Sharp Chula Vista Medical Center
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More informationa. A pharmacist may order a baseline SCr per protocol
UNITYPOINT HEALTH - MARSHALLTOWN Marshalltown, Iowa PHARMACY POLICY AND PROCEDURE Subject: Anticoagulant Therapy Per Practice Protocol (Formerly Anticoagulant therapy #NPSG.03.05.01) Inpatient Warfarin
More informationAtrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted.
Patient Name: Diagnosis: Allergies with reaction type: Atrial Fibrillation Version 2 11/4/15 This order set must be used with an admission order set if patient not already admitted. Telemetry Medical Telemetry:
More informationPreventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE
Preventing Stroke in Patients with Atrial Fibrillation: USING THE EVIDENCE What Is Atrial Fibrillation? Atrial fibrillation also called AFib or AF is the most common abnormal heart rhythm, affecting an
More informationMedications for Treating Stroke
Medications for Treating Stroke Subject Expert Sonny Kupniewski, PharmD, BCPS Swedish Medical Center Englewood, CO 2 Objectives Medications used to prevent stroke Prevention of strokes in patients with
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationPrimary Care Patient Case Example
Primary Care Patient Case Example Chief Complaint (CC): K.G. presents to your clinic for a follow-up. You work in an interprofessional clinic with physicians. He has no complaints today. History of the
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationDEPRESCRIBING IN THE ELDERLY
DEPRESCRIBING IN THE ELDERLY G E R I A T R I C S R E F R E S H E R D A Y W E D N E S D A Y, A P R I L 5 TH, 2 0 1 7 V É R O N I Q U E F R E N C H M E R K L E Y, M D, C C F P ( C O E ) B R U Y È R E C O
More informationCase 1. Case 2. What do you think about reducing or discontinuing some of the above now that his LVEF has normalized?
Case 1 A primary care colleague inquires what to do with a patient (HFrEF in NSR) who has a digoxin level of 2.8ng/ml. Level was obtained at 10am, patient takes all medications at one time upon arising
More informationProfile number: 3 MSc Clinical Pharmacy / Clinical and Health Services Pharmacy. Patient Profile
Patient Profile Patient background and medication list Reason for selecting profile Heart Failure is a topic we have studied this semester and I would like to apply my learning to this area. I found this
More informationScenario Development Template
Scenario Development Template Scenario Title: Inf STEMI, ICH, PEA Arrest Author: E. Merrick Last edit: April 12, 2018 Set up: Confederates: Duration: Scenario 20 min Debriefing 30 min Learning Objectives:
More informationCycle 1 PERTuzumab (day 1) and trastuzumab (day 2) loading doses: Drug Dose BC Cancer Administration Guideline
BC Cancer Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using PERTuzumab, Trastuzumab (HERCEPTIN), and PACLItaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code:
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationEffect on sudden death
Effect on sudden death of heart failure treatment started with bisoprolol followed by enalapril, compared to the opposite order: Results of the randomized CIBIS III trial Ronnie Willenheimer Ass. Prof.
More information[ Na+] COI Disclosure OBJECTIVES. By the end of the session, and upon further learning and reflection participants should be able to:
COI Disclosure Busting Myths and de-mist-ifying its Assessment & Management Peter Loewen B.Sc.(Pharm), ACPR, Pharm.D., FCSHP Faculty of Pharmaceutical Sciences The University of British Columbia Lower
More informationCase Study #2. Case Study #1 cont 9/28/2011. CAPA 2011 Christy Wilson PA C. LH is 78 yowf with PMHx of metz breast CA presents
Case Study #1 CAPA 2011 Christy Wilson PA C 46 yo female presents with community acquired PNA (CAP). Her condition worsened and she was transferred to the ICU and placed on mechanical ventilation. Describe
More informationDysnatremias: All About the Salt? Internal Medicine Resident Lecture 1/12/16 Steve Schinker, MD
Dysnatremias: All About the Salt? Internal Medicine Resident Lecture 1/12/16 Steve Schinker, MD Water or salt? Dysnatremias In general, disorder of water balance, not sodium balance Volume status is tied
More informationCASE STUDIES IN ADVANCED HEART FAILURE
CASE STUDIES IN ADVANCED HEART FAILURE Navin Rajagopalan, MD Director, Congestive Heart Failure Medical Director, Cardiac Transplantation Gill Heart Institute, Cardiovascular Medicine DISCLOSURES NOTHING
More informationReview guidance for patients on long-term amiodarone treatment
Review guidance for patients on long-term amiodarone treatment This review guidance document has been produced in response to: 1. Current supply shortages of branded and generic versions of 100mg and 200mg
More informationAtrial Fibrillation. Ivan Anderson, MD RIHVH Cardiology
Atrial Fibrillation Ivan Anderson, MD RIHVH Cardiology Outline Definition and Pathophysiology Rate versus rhythm control Rate control thresholds (how much is enough) Anti-coagulation CHADS2VASc score HASBLED
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More information심방세동과최신항응고요법 RACE II AFFIRM 항응고치료는왜중요한가? Rhythm control. Rate control. Anticoagulation 남기병 서울아산병원내과. Clinical Impact of Atrial Fibrillation
소강당 심방세동과최신항응고요법 남기병 서울아산병원내과 Clinical Impact of Atrial Fibrillation QoL Hospitalization Stroke CHF Mortality 항응고치료는왜중요한가? Rhythm control Rate control Anticoagulation JACC Vol. 38, No. 4, 2001 AFFIRM RACE
More informationHeart Failure Update. Bibiana Cujec MD May 2015
Heart Failure Update Bibiana Cujec MD May 2015 Disclosures Participation in clinical trial GUIDE IT (BNP in management of HF) Plan Review of new trials/ccs guidelines Management of heart failure: cases
More informationWhat s New in the AF Guidelines
Impact on New AF Guidelines on Heart Failure Management Gothenburg - May 22 nd 2011 Europace (2010) 12, 1360-420 http://europace.oxfordjournals.org JACC (2011) 57, 223-42 http://www.cardiosource.org What
More information